LOGIN  |  REGISTER
Chimerix

Inari Medical to Present at Upcoming Investor Conferences

November 02, 2023 | Last Trade: US$79.97 0.00 0.00

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:

  • Jefferies London Healthcare Conference
    Presenting on Wednesday, November 15 at 11:00 a.m. Greenwich Mean Time / 6:00 a.m. Eastern Time in London, England at the Waldorf Hilton
  • 35th Annual Piper Sandler Healthcare Conference
    Presenting on Wednesday, November 29 at 4:00 p.m. Eastern Time in New York, NY at The Lotte New York Palace

The live audio webcasts and replays of the presentations may be accessed on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.

Investor Contact:

John Hsu, CFA
VP, Investor Relations
949-658-3889
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page